Mutation Linked to Increased Risk of Prostate Cancer Mortality
The risk of dying of prostate cancer doubled in the presence of a genetic mutation affecting testosterone production, a large prospective cohort study showed. The 5-year risk of prostate cancer-specific mortality (PCSM) increased from 1.7% to as much as 4%, depending on the genotype of the HSD3B1(1245C) allele. In a subgroup of patients with metastatic […]
What Is Luminal B Breast Cancer? Olivia Munn’s Diagnosis Explained.
Phillip Faraone/VF24 via Getty Images Luminal B breast cancer tends to be more aggressive and often presents at later stages. Actress Olivia Munn announced on Instagram that she was diagnosed with breast cancer in 2023. Specifically, Munn was diagnosed with luminal B breast cancer, which is one of the molecular subtypes of breast cancer, according […]
Many ‘High-Risk’ Americans Unconcerned About Skin Cancer: Poll
Latest Cancer News FRIDAY, June 18, 2021 (HealthDay News) It’s long been known the sun’s rays can cause skin cancer. But a new poll shows that only about 30% of American adults say they’re concerned about developing skin cancer — even though nearly 70% have at least one risk factor for the disease. […]
In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according to results from a retrospective cohort study. Compared with white women, Black women with TNBC were less likely to achieve pCR (OR 0.89, 95% CI 0.83-0.95, […]
What We Know About King Charles III’s Health History
The announcement Monday that King Charles III has been diagnosed with cancer has come as a shock to many in Britain, largely because the 75-year-old monarch has generally enjoyed good health through the years. Palace officials did not specify what kind of cancer the king has, or how serious his condition is. They only said […]
King Charles III Has Cancer
Britain’s King Charles III has been diagnosed with cancer and has begun treatment, Buckingham Palace said Monday. Less than 18 months into his reign, the 75-year-old monarch will suspend public engagements but will continue with state business, and won’t be handing over his constitutional roles as head of state. The palace didn’t disclose what form […]
Improved Fitness May Reduce Prostate Cancer Risk
Improving cardiorespiratory fitness may lower men’s prostate cancer risk, results from a Swedish study suggested. The retrospective study showed that an overall increase in absolute cardiorespiratory fitness (as measured by changes in VO2max) was associated with a 2% reduced risk of prostate cancer incidence (HR 0.98, 95% CI 0.96-0.99), when adjusted for baseline fitness, age, […]
Peripheral IV Access for Chemo Better Than Central Lines in Testicular Cancer?
Patients with testicular cancer had fewer venous access-related complications and overall thrombotic events when first-line chemotherapy was delivered via peripheral intravenous access compared with central venous access devices (CVADs), a retrospective study suggested. Among 154 patients, those in the CVAD group compared with the peripheral IV group experienced more venous access-related complications (52.2% vs 24.2%) […]
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing
SAN FRANCISCO — A multiparametric blood test for prostate cancer showed potential to avoid more than half of unnecessary biopsies without sacrificing accuracy, a large prospective study showed. In a comparison against the current PSA testing standard of ≥4 ng/mL, the Stockholm3 biomarker, which incorporates a PSA cutoff of 15 ng/mL with other proteins and […]
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC
SAN FRANCISCO — In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved radiographic progression-free survival (rPFS) versus a switch to a second hormonal agent, a phase III trial showed. The so-called CONTACT-02 study included patients with extrapelvic nodal or […]